Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis

Prostate

Volumn 51, Issue 3, 2002, Pages 189-200

  Luo, Jun ^a   Dunn, Thomas ^b   Ewing, Charles ^c   Sauvageot, Jurga ^a   Chen, Yidong ^a   Trent, Jeffrey ^b   Isaacs, William ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c 115 Marburg ^*  (United States)

Author keywords

Benign prostatic hyperplasia; cDNA microarray; Gene expression profiling

Indexed keywords

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

ADULT; AGED; AGED, 80 AND OVER; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC HYPERPLASIA;

EID: 0037093815     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10087     Document Type: Article

References (51)

1. Pathology of benign prostatic hyperplasia. Insight into etiology
2. Benign prostatic hyperplasia
3. The development of human benign prostatic hyperplasia with age
4. Etiology of benign prostatic hyperplasia
5. Etiology and disease process of benign prostatic hyperplasia
6. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture
7. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia
8. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells
9. Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: Relationship with binding proteins 2 and 3 and androgens
10. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type 1 in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens
11. Insulin-like growth factors and their binding proteins: Biological actions
12. Insulin-like growth factor receptors
13. The insulin-like growth factor-binding protein superfamily
14. Extracellular matrix containsinsulin-like growth factor binding protein-5: Potentiation of the effects of IGF-I
15. Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not
16. Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia
17. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation
18. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy
19. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma
20. Benign prostatic hyperplasia
21. Identification of genes differentially expressed in benign prostatic hyperplasia
22. Quantitative monitoring of gene expression patterns with a complementary DNA microarray
23. Expression profiling using cDNA microarrays
24. Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling
25. Pieces of the puzzle: Expressed sequence tags and the catalog of human genes
26. Molecular classification of cutaneous malignant melanoma by gene expression profiling
27. Ratio-based decisions and the quantitative analysis of cDNA microarray images
28. Gene-expression profiles in hereditary breast cancer
29. Clooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma
30. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins
31. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7: Recombinant human mac25 protein specifically binds IGF-I and -II
32. Latent-TGF-beta: An overview
33. Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue
34. Transforming growth factor-beta 3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma
35. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue
36. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin
37. Alpha 2-macroglobulin: A binding protein for transforming growth factor-beta and various cytokines
38. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia
39. The quiescin Q6 gene (QSCN6) is a fusion of two ancient gene families: Thioredoxin and ERV1
40. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
41. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues
42. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis
43. Thrombospondin-4 binds specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-terminal domains
44. Pathology of benign prostatic hyperplasia
45. The prostate and seminal vesicles
46. Normal histology of the prostate
47. Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer. Morphometric analysis in whole-mount sections
48. Histopathologic characterization of hereditary benign prostatic hyperplasia
49. Enhanced expression of the mesenchymal marker, vimentin, in hyperplastic versus normal human prostatic epithelium
50. Anatomy of the prostate and morphogenesis of BPH
51. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues